{"id":2520,"date":"2024-05-10T13:20:19","date_gmt":"2024-05-10T13:20:19","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2520"},"modified":"2024-05-10T13:20:20","modified_gmt":"2024-05-10T13:20:20","slug":"novavaxs-strategic-leap-in-vaccine-development","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/","title":{"rendered":"Novavax&#8217;s Strategic Leap in Vaccine Development"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Novavax&#8217;s Financial Outlook and Expedites COVID-19 and Influenza Vaccine Initiatives<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Novavax (NVAX), a leading vaccine developer, has announced a groundbreaking co-exclusive licensing agreement with Sanofi (SNY), signaling a significant milestone in the fight against COVID-19 and influenza. The deal encompasses the co-commercialization of COVID-19 vaccines, the development of novel COVID-19-Influenza combination vaccines, and the exploration of multiple new vaccine opportunities leveraging Novavax&#8217;s Matrix-MTM adjuvant technology.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This partnership represents a substantial revenue opportunity for Novavax, with an impressive package including a $500 million upfront payment, equity investment, near-term milestones totaling up to $700 million, and ongoing royalties on product sales. Additionally, Novavax stands to gain up to $200 million in milestones plus royalties for each new vaccine developed with its Matrix-MTM adjuvant.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The announcement has sparked investor optimism, driving Novavax shares to double in value. The company&#8217;s successful reduction of current liabilities by $831 million in Q1 2024 further underscores its financial stability and growth potential.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In alignment with its commitment to innovation and public health, Novavax has expanded its vaccine portfolio to include a standalone influenza vaccine, augmenting its Phase 3 COVID-19-Influenza Combination vaccine trial. With plans to initiate trials in the second half of 2024 and potential launch by 2026, Novavax aims to address critical public health needs and enhance its market presence.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s executives have expressed confidence in meeting key milestones, with anticipation of data readouts for both COVID-19 and influenza vaccines by mid-2025. Moreover, the strategic collaboration with Sanofi is expected to yield substantial royalties and milestones, surpassing the value of Novavax&#8217;s independent efforts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As Novavax navigates its transition from innovator to commercial leader, its partnership with Sanofi heralds a new era of accelerated vaccine development and global healthcare impact.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2024\/05\/09\/roblox-adjusts-annual-forecasts-amid-economic-uncertainty\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Roblox Adjusts Annual Forecasts Amid Economic Uncertainty<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novavax&#8217;s Financial Outlook and Expedites COVID-19 and Influenza Vaccine Initiatives Novavax (NVAX), a leading vaccine developer, has announced a groundbreaking co-exclusive licensing agreement with Sanofi (SNY), signaling a significant milestone in the fight against COVID-19 and influenza. The deal encompasses the co-commercialization of COVID-19 vaccines, the development of novel COVID-19-Influenza combination vaccines, and the exploration [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1410,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[308,360],"tags":[438,421,437],"coauthors":[],"class_list":["post-2520","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-mid-cap","tag-covid-19","tag-growth","tag-licensing"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novavax&#039;s Strategic Leap in Vaccine Development - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novavax&#039;s Strategic Leap in Vaccine Development - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Novavax&#8217;s Financial Outlook and Expedites COVID-19 and Influenza Vaccine Initiatives Novavax (NVAX), a leading vaccine developer, has announced a groundbreaking co-exclusive licensing agreement with Sanofi (SNY), signaling a significant milestone in the fight against COVID-19 and influenza. The deal encompasses the co-commercialization of COVID-19 vaccines, the development of novel COVID-19-Influenza combination vaccines, and the exploration [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-10T13:20:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-10T13:20:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"Novavax&#8217;s Strategic Leap in Vaccine Development\",\"datePublished\":\"2024-05-10T13:20:19+00:00\",\"dateModified\":\"2024-05-10T13:20:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/\"},\"wordCount\":302,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-artem-podrez-4492047-scaled.jpg\",\"keywords\":[\"COVID-19\",\"Growth\",\"licensing\"],\"articleSection\":[\"Biotechnology\",\"Mid-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/\",\"name\":\"Novavax's Strategic Leap in Vaccine Development - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-artem-podrez-4492047-scaled.jpg\",\"datePublished\":\"2024-05-10T13:20:19+00:00\",\"dateModified\":\"2024-05-10T13:20:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-artem-podrez-4492047-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-artem-podrez-4492047-scaled.jpg\",\"width\":2560,\"height\":1440,\"caption\":\"vaccine-2\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/05\\\/10\\\/novavaxs-strategic-leap-in-vaccine-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novavax&#8217;s Strategic Leap in Vaccine Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novavax's Strategic Leap in Vaccine Development - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/","og_locale":"en_US","og_type":"article","og_title":"Novavax's Strategic Leap in Vaccine Development - Stoxpo","og_description":"Novavax&#8217;s Financial Outlook and Expedites COVID-19 and Influenza Vaccine Initiatives Novavax (NVAX), a leading vaccine developer, has announced a groundbreaking co-exclusive licensing agreement with Sanofi (SNY), signaling a significant milestone in the fight against COVID-19 and influenza. The deal encompasses the co-commercialization of COVID-19 vaccines, the development of novel COVID-19-Influenza combination vaccines, and the exploration [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/","og_site_name":"Stoxpo","article_published_time":"2024-05-10T13:20:19+00:00","article_modified_time":"2024-05-10T13:20:20+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"Novavax&#8217;s Strategic Leap in Vaccine Development","datePublished":"2024-05-10T13:20:19+00:00","dateModified":"2024-05-10T13:20:20+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/"},"wordCount":302,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","keywords":["COVID-19","Growth","licensing"],"articleSection":["Biotechnology","Mid-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/","name":"Novavax's Strategic Leap in Vaccine Development - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","datePublished":"2024-05-10T13:20:19+00:00","dateModified":"2024-05-10T13:20:20+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-artem-podrez-4492047-scaled.jpg","width":2560,"height":1440,"caption":"vaccine-2"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/05\/10\/novavaxs-strategic-leap-in-vaccine-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Novavax&#8217;s Strategic Leap in Vaccine Development"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2520"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2520\/revisions"}],"predecessor-version":[{"id":2521,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2520\/revisions\/2521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1410"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2520"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}